Literature DB >> 21836611

Survival of patients with clinically identified monoclonal B-cell lymphocytosis (MBL) relative to the age- and sex-matched general population.

T D Shanafelt, N E Kay, K G Rabe, T G Call, C S Zent, S M Schwager, J F Leis, D F Jelinek, S L Slager, C A Hanson.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21836611     DOI： 10.1038/leu.2011.211

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  8 in total

Review 1.  Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification.

Authors:  Paolo Strati; Tait D Shanafelt
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

Review 2.  Monoclonal B cell lymphocytosis--what does it really mean?

Authors:  Andy C Rawstron
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

3.  Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis.

Authors:  Sameer A Parikh; Kari G Chaffee; Melissa C Larson; Paul J Hampel; Timothy G Call; Wei Ding; Saad S Kenderian; Jose F Leis; Asher A Chanan-Khan; Michael J Conte; Deborah Bowen; Susan M Schwager; Susan L Slager; Curtis A Hanson; Neil E Kay; Tait D Shanafelt
Journal:  Haematologica       Date:  2018-02-01       Impact factor: 9.941

4.  Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines.

Authors:  Timothy G Call; Aaron D Norman; Curtis A Hanson; Sara J Achenbach; Neil E Kay; Clive S Zent; Wei Ding; James R Cerhan; Kari G Rabe; Celine M Vachon; Emily J Hallberg; Tait D Shanafelt; Susan L Slager
Journal:  Cancer       Date:  2014-04-07       Impact factor: 6.860

5.  Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis.

Authors:  B M Solomon; K G Chaffee; J Moreira; S M Schwager; J R Cerhan; T G Call; N E Kay; S L Slager; T D Shanafelt
Journal:  Leukemia       Date:  2015-08-27       Impact factor: 11.528

Review 6.  Targeting Mitochondrial Bioenergetics as a Therapeutic Strategy for Chronic Lymphocytic Leukemia.

Authors:  Subir Roy Chowdhury; Versha Banerji
Journal:  Oxid Med Cell Longev       Date:  2018-02-28       Impact factor: 6.543

7.  Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcome.

Authors:  Ignacio Criado; Arancha Rodríguez-Caballero; M Laura Gutiérrez; Carlos E Pedreira; Miguel Alcoceba; Wendy Nieto; Cristina Teodosio; Paloma Bárcena; Alfonso Romero; Paulino Fernández-Navarro; Marcos González; Julia Almeida; Alberto Orfao
Journal:  Haematologica       Date:  2018-03-22       Impact factor: 9.941

8.  Evolving DNA methylation and gene expression markers of B-cell chronic lymphocytic leukemia are present in pre-diagnostic blood samples more than 10 years prior to diagnosis.

Authors:  Panagiotis Georgiadis; Irene Liampa; Dennie G Hebels; Julian Krauskopf; Aristotelis Chatziioannou; Ioannis Valavanis; Theo M C M de Kok; Jos C S Kleinjans; Ingvar A Bergdahl; Beatrice Melin; Florentin Spaeth; Domenico Palli; R C H Vermeulen; J Vlaanderen; Marc Chadeau-Hyam; Paolo Vineis; Soterios A Kyrtopoulos
Journal:  BMC Genomics       Date:  2017-09-13       Impact factor: 3.969
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.